Heparin Holly

The story

Holly's heparin drip has run for two days for her DVT. This morning her aPTT is 110 seconds (control 30), she has oozing at her IV site, and her platelet count has fallen by half since admission.

Holly is a veteran air traffic controller famous among her colleagues for her ability to track dozens of moving flight paths simultaneously without ever losing focus on a single one. That vigilant, multi-tracking mindset becomes essential to her own survival after she develops a deep vein thrombosis in her calf following a long-haul flight and is started on an intravenous heparin infusion. Heparin works quickly by activating antithrombin III, which immediately inhibits thrombin and factor Xa, preventing her existing clot from extending further while her body works to naturally dissolve it. Because heparin interferes with clotting throughout her entire body, not just at the site of her clot, the central danger it carries is bleeding, whether from her gums, her urine, or far more seriously, inside her brain. A separate, distinct threat also lurks in the form of heparin-induced thrombocytopenia, a paradoxical immune reaction that causes new clots to form even as platelet counts fall.

Holly's care team places her on a weight-based intravenous heparin protocol, drawing an activated partial thromboplastin time, or aPTT, every six hours to keep her within the therapeutic range of roughly one and a half to two and a half times the control value. For the first four days, her infusion rate is adjusted several times as her aPTT results fluctuate slightly, but she remains stable, and her calf swelling and tenderness begin to noticeably improve. Her nurse also draws a baseline platelet count on admission, fully aware that Holly's ongoing heparin exposure over the coming days carries a specific risk that develops on a very particular and predictable timeline.

On day seven of her heparin infusion, Holly's routine complete blood count reveals her platelet count has fallen from a baseline of 240,000 to just 95,000 per microliter, a drop of more than fifty percent. Rather than developing signs of bleeding, however, Holly suddenly complains of new, sharp pain and swelling in her opposite leg, and her nurse notes new coolness and diminished pulses in that limb on assessment. This paradoxical combination, a falling platelet count paired with new clot formation rather than bleeding, occurring at exactly the classic five-to-ten-day window after starting heparin, is the unmistakable signature of heparin-induced thrombocytopenia, a serious immune-mediated complication that demands immediate recognition rather than being dismissed as an unrelated new clot.

The nurse immediately stops the heparin infusion and, critically, ensures that every source of heparin exposure is discontinued, including heparin flushes used for her intravenous line, since even trace amounts can perpetuate the immune reaction. She notifies the provider urgently, anticipates orders for an alternative non-heparin anticoagulant to manage Holly's ongoing clot risk, and closely monitors the newly affected limb for perfusion and pulses. She clearly documents heparin-induced thrombocytopenia in Holly's chart and flags it prominently so that no formulation of heparin, including low-molecular-weight versions, is ever administered to her again. Throughout, she remains vigilant for bleeding as well, understanding that Holly's care now requires simultaneously watching for both hemorrhage risk from her recent anticoagulation and new clot formation from this immune complication.